Skip to main content
Equibles
ORKA logo

ORKA · Oruka Therapeutics, Inc. · Metrics

Track ORKA — free

Use ORKA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ORKA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$91.50 -2.81 (-2.98%) At close · Sep 9
Russell 2000 member Rebalance outlook locked
Market Cap
$6.06B
Shares
66.21M

ORKA metrics

56 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$91.50
Market cap
$6.06B

Price action

20 metrics
Price change (1W)
+2.4%
Price change (30D)
-10.3%
Price change (3M)
+40.9%
Price change (6M)
+179.9%
Price change (YTD)
+211.2%
Price change (1Y)
+496.9%
Trailing year
Price change (5Y)
—
52-week high
$113.08
52-week low
$14.90
Change from 52-week high
-16.6%
Change from 52-week low
+533.0%
Annualized volatility
75.9%
Annualized volatility (3M)
67.4%
Beta
1.5
RSI (14D)
45.5
Price vs SMA 50
-1.2%
Price vs SMA 200
+61.1%
Avg volume (3M)
1.17M
Relative volume
0.7
Average dollar volume
$104.77M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
66.21M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
5.4
reciprocal yield 18.4%
FCF yield
-1.7%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-2.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
2024-08-29

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-04-30

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$155.08M
Net income (TTM)
−$132.89M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$9.69

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,216.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-11.9%
Return on assets
-11.7%
Debt / equity
—
Current ratio
38.5
EBITDA (TTM)
−$27.49M
Free cash flow (TTM)
−$101.15M
Quick ratio
38.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$873.56M
Latest balance sheet
Cash & equivalents
$268.47M
Total assets
$1.14B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$100.92M
Capital expenditures (TTM)
$235,000
R&D (TTM)
$129.03M
SG&A (TTM)
$4.20M
Stock compensation (TTM)
$28.53M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
258
13F filer change QoQ
+73
Institutional ownership
112.5%

Short interest

3 metrics
Short interest
12.5%
Latest settlement · 11.3 days to cover
Days to cover
11.3d
Short-squeeze score
78 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$319.24M
Insider-sentiment score
4 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 907654 CUSIP 687604108 13F (30d) 171 filings 171 filers Visit website Investor relations